Type 2 Diabetes

Insulin-focused therapeutics company expands trials of type 2 diabetes treatment

Published in Genomics and Genetics Weekly, February 25th, 2005

Transition Therapeutics Inc. (TTH) announced that it has received clearance from the United States Food and Drug Administration (FDA) to initiate a clinical trial for its lead diabetes product, E1-I.N.T., in type 2 diabetes patients.

E1-I.N.T. is a short course combination therapy aimed at stimulating the regeneration of the body's insulin-producing cells.

Similar to the previously announced clinical trial in type I diabetes, this type 2 diabetes clinical trial will be conducted in the United States and will evaluate the efficacy, safety, and tolerability of a 28-day course of daily E1-I.N.T. treatments with a 6-month follow-up.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly

Source: Genomics and Genetics Weekly (2005-02-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry